Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment

Hayoung Lee1, Young Hoon Kim2, Seong Jun Lim2, Youngmin Ko2, Sung Shin2, Joo Hee Jung2, Chung Hee Baek2, Hyosang Kim3, Su-Kil Park3, Hyunwook Kwon2

1Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

INTRODUCTION

Kidney transplantation (KT) is the treatment of choice to improve patient quality of life and long-term survival in end-stage renal disease [1]. One significant obstacle to achieving a successful survival rate is increased malignancy-related mortality compared with the general population [1-3]. The risk of cancer in recipients is attributed mainly to chronic use of immunosuppressants and altered T-cell immunity [4]. Recently, transplants across immunologic barriers, including among patients with blood groups A and B and human leukocyte antigen (HLA) antibodies, have increased...
These immunologically high-risk transplant patients require desensitization treatment using plasmapheresis, rituximab (Genentech, Inc., San Francisco, CA, USA), and intravenous immunoglobulin (IVIG) and maintenance of a high concentration of a calcineurin inhibitor (CNI) [6]. Although intense immunosuppression provides a survival benefit for patients waiting for a compatible donor, side effects, including mortality from infectious complications, BK virus infection, and postoperative bleeding, are also increased [5,7,8].

Rituximab, an anti-CD20 monoclonal antibody that depletes peripheral blood B cells for 3–12 months, has been increasingly used for therapeutic purposes for pretransplant desensitization and rejection treatment after KT [9]. Host immune cells play a crucial role in antitumor mechanisms, and T cells have recently been applied to therapeutic advancements in cancer treatment such as chimeric antigen receptor-T cell therapies and checkpoint inhibitors [10]. B cells have also been found to play essential roles in suppressing tumor progression through humoral immunity and local immune reactions with tertiary lymphoid organs [3]. However, only a few studies with a small number of patients have evaluated the effect of rituximab on cancer development following KT [11-13]. Furthermore, rituximab increases the risk of infectious complications, including viral, bacterial, and lethal fungal infections [14,15]. Considering that immunosuppression increases the incidence of virus-related cancer, such as Kaposi sarcoma, cervical cancer, and hepatocellular carcinoma (HCC), and that East Asia is an endemic area of HBV infection, there is a need to evaluate the impact of rituximab treatment on cancer development [16,17].

In this study, we reviewed the incidence of malignant disease in a large single-center cohort and evaluated the effect of rituximab on the cancer occurrence and mortality rate according to each type of cancer.

**METHODS**

**Patients**

This was a retrospective study using a database obtained by reviewing the medical records from Asan Medical Center (AMC) in Seoul, Korea. We included 5,000 consecutive recipients who underwent KT at AMC between January 1990 and January 2018. We divided the study cohort into era1 (1990–2007) and era2 (2008–2018) because our center started to perform HLA- and ABO-incompatible KT in 2008. The patients in era2 also were divided into non-rituximab (era2-rit−) and rituximab groups (era2-rit+) to evaluate the effect of rituximab. The era2-rit+ group included patients who received single-dose rituximab (200–500 mg) as a desensitization treatment 1–2 weeks before KT [5].

The Institutional Review Board of AMC approved this study (No. AMC 2021-0498) and waived informed consent due to the retrospective nature of this study using data from patients’ medical records. No organs/tissues were procured from any vulnerable populations, and all donors or next of kin provided written informed consent that was freely given. Organs/tissues were procured only at registered institutions with The Korean Network for Organ Sharing, which is a nationwide system of deceased donor detection and distribution.

**Immunosuppression**

When we started performing KT at our center in 1990, we used an immunosuppressive regimen consisting of cyclosporin, corticosteroids, and azathioprine without an induction drug. Since the mid-1990s, we have increased the usage of tacrolimus as a CNI, and more than 80% of recent transplant recipients have received tacrolimus. Azathioprine is no longer in use and has been replaced by mycophenolic acid. Patients have received basiliximab (Simulect, Novartis, East Hanover, NJ, USA) as an induction therapy since 1999. Recently, we have used rabbit antithymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA, USA) in highly sensitized recipients. In ABO-incompatible and crossmatch-positive KT, recipients receive a single dose of rituximab (200–500 mg) 2–3 weeks before transplantation and plasmapheresis with/without IVIG according to the desensitization protocol of our center [5].

**Cancer screening**

According to the National Cancer Screening Program (N CSP) in South Korea and our transplant program protocol, all transplant candidates undergo cancer screening [18]. We perform esophagogastroduodenoscopy (for patients aged ≥16 years), colonoscopy (for patients aged ≥40 years), and abdominal ultrasonography (USG). Non-contrast-enhanced abdominopelvic CT has replaced abdominal USG since November 2013. In addition, female patients undergo a Papanicolaou test with a gynecological examination and mammography, and male patients undergo measurement of PSA levels. After transplantation, we recommend that all recipients undergo cancer screening tests according to the N CSP guidelines. Patients with chronic HBV infection undergo abdominal USG and have α-FP levels evaluated every 6–12 months [19].

**Statistical analysis**

Categorical variables were assessed by the chi-square test and are presented as counts and percentages. Normally distributed continuous variables are shown as the mean ± standard deviation, and nonnormally distributed continuous variables are presented as medians and interquartile ranges (IQRs). Analysis of variance and the Kruskal-Wallis test were used to analyze continuous variables among the 3 groups, as appropriate. The survival rate was evaluated by Kaplan-Meier analysis and compared with the log-rank test. The risk factors for cancer
and cancer-related mortality following KT were evaluated by univariate and multivariate Cox proportional hazards regression analysis. Recipients in the groups era2-rit– and era2-rit+ were selected by a maximum 3:1 match based on propensity scores. The variables for propensity matching included age, sex, body mass index (BMI), diabetes mellitus (DM), HBV infection, CNI, HLA mismatch, and living vs. deceased donor. A standardized difference of <0.1 was considered balanced. All statistical analyses were performed in IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA), and a P-value of 0.05 was considered a significant cutoff value.

RESULTS

Patient demographic and clinical characteristics

The 5,000 consecutive recipients who underwent KT at our center were divided into the era1 (n = 2,105, 42.1%), era2-rit– (n = 2,273, 45.5%), and era2-rit+ groups (n = 622, 12.4%). The baseline demographics of this study are demonstrated in Table 1. The era2-rit– and era2-rit+ groups had significantly higher proportions of older patients (P < 0.001), female patients (P = 0.001), patients with DM (P < 0.001), and patients with hypertension (P < 0.001) than the era1 group. More patients in the era1 group than in the other 2 groups were HBV carriers (P < 0.001). More patients in the era2-rit– and era2-rit+ groups than in the era1 group used tacrolimus instead of cyclosporin (P < 0.001). There were 233 (11.1%), 65 (2.9%), and 12 cases (1.9%) of posttransplant malignancies in the era1, era2-rit–, and era2-rit+ groups, respectively, during a mean follow-up period of 212 ± 78, 83 ± 37, and 72 ± 31 months, respectively (P < 0.001). Urologic malignancy was the most frequently identified cancer (n = 53, 17.1%) after KT, followed by thyroid (n = 40, 12.9%), hematologic (n = 36, 11.6%), colorectal (n = 31, 10.0%), breast (n = 26, 8.4%), and stomach (n = 25, 8%) cancer (Fig. 1). The median (IQR) time from transplantation to cancer occurrence was 21 months (14–33 months) for Kaposi sarcoma, 54 months (32–116 months) for skin cancer, 56 months (20–126 months) for HCC, 66 months (35–115 months) for stomach cancer, 72 months (21–141 months) for thyroid cancer, 73 months (29–129 months) for hematologic cancer, 76 months (53–124 months) for

Table 1. Baseline and clinical characteristics of the study patients (n = 5,000)

| Characteristic                        | Era1 (1990–2007) | Era2 (2008–2018) | P-value |
|---------------------------------------|------------------|------------------|---------|
| Patient                               | 2,105 (42.1)     | 2,273 (45.5)     | 622 (12.4) | NA     |
| Age (yr)                              | 38.5 ± 11.7      | 45.9 ± 11.9      | 47.2 ± 11.8 | <0.001 |
| Female sex                            | 801 (38.1)       | 956 (42.1)       | 287 (46.1) | 0.001  |
| Diabetes mellitus                     | 278 (14.9)       | 573 (25.2)       | 160 (25.7) | <0.001 |
| Hypertension                          | 1,517 (72.1)     | 1,940 (85.3)     | 542 (87.1) | <0.001 |
| HBV                                   | 110 (5.2)        | 89 (3.9)         | 16 (2.6)   | <0.001 |
| HCV                                   | 61 (2.9)         | 31 (1.4)         | 18 (2.9)   | 0.001  |
| Dialysis duration (mo)                | 12 (4–36)        | 16 (2–71)        | 8 (2–29)   | <0.010 |
| Body mass index (kg/m²)               | 22 (20–24)       | 22 (20–24)       | 23 (20–25) | 0.190  |
| ABO incompatible                       | 0 (0)            | 0 (0)            | 494 (79.4)| NA     |
| FCXM positive                         | 0 (0)            | 0 (0)            | 179 (28.8)| NA     |
| CDC positive                          | 0 (0)            | 0 (0)            | 33 (5.3)   | NA     |
| HLA-A,-B,-DR mismatch                 | 3 (2–4)          | 3 (2–4)          | 3 (2–5)   | <0.001 |
| PRA class I                           | 0 (0–0)          | 0 (0–11)         | 0 (0–11)  | <0.001 |
| PRA class II                          | 0 (0–0)          | 0 (0–7)          | 0 (0–30)  | <0.001 |
| Cadaveric donor                       | 479 (22.8)       | 675 (29.7)       | 0 (0)     | <0.001 |
| Living donor                          | 1,626 (77.2)     | 1,598 (70.3)     | 622 (100) | <0.001 |
| Calcineurin inhibitor                  | 585 (27.8)       | 1,759 (77.4)     | 500 (80.4) | <0.001 |
| Tacrolimus                            | 1,520 (72.2)     | 517 (22.7)       | 122 (19.6) | <0.001 |

Values are presented as number (%), mean ± standard deviation, and median (interquartile range).

NA, not applicable; FCXM, flow cytometry crossmatch; CDC, complement-dependent cytotoxicity; HLA, human leukocyte antigen; PRA, panel reactive antibody.
lung cancer, 87 months (27–103 months) for biliary-pancreatic (BP) cancer, 94 months (58–160 months) for breast cancer, 115 months (73–157 months) for urologic cancer, and 148 months (73–204 months) for colorectal cancer (Fig. 2).

**Risk factors for cancer-related mortality**

In the multivariate regression analysis, age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.01–1.04; P < 0.001) and BMI (HR, 1.01; 95% CI, 1.00–1.01; P = 0.001) were significant risk factors for malignant disease after transplant. However, rituximab had no significant association (Table 2).

The propensity match analysis showed that rituximab did not increase the risk of cancer following KT HCC (HR, 1.36; 95% CI, 0.72–2.57; P = 0.348) (Table 3). The overall cancer-related mortality rate was 17.1% (53 of 310). HCC (61.5%) had the highest mortality rate, followed by BP (53.8%), lung (31.3%), oropharyngeal (33.3%), and stomach cancer (28.0%). The relative risk of cancer-related death stratified by the type of malignancy was significantly high among patients with HCC (HR, 8.29; 95% CI, 2.40–28.69; P = 0.001), BP cancer (HR, 5.41; 95% CI, 1.46–20.12; P = 0.012), and oropharyngeal cancer (HR, 4.54; 95% CI, 0.98–21.04; P = 0.053) after adjusting for the following risk factors: age, BMI, sex, DM, and rituximab treatment (Table 4). The 5-year incidence rates of malignant tumors after KT were 3.1%, 4.3%, and 3.5% in the era1, era2-rit–, and era2-

![Fig. 1. Incidence of cancer (ca.) after kidney transplantation. BP, biliary-pancreatic.](image1)

![Fig. 2. Time to cancer (ca.) development after kidney transplantation. BP, biliary-pancreatic.](image2)

**Table 2.** Risk factors associated with cancer after transplantation

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | P-value               | HR (95% CI)         | P-value               |
| Age                             | 1.03 (1.02–1.04)    | <0.001                | 1.03 (1.01–1.04)    | <0.001                |
| Male sex                        | 1.28 (1.02–1.60)    | 0.032                 | 1.25 (0.99–1.59)    | 0.060                 |
| Year of transplant              | 1.01 (0.99–1.03)    | 0.248                 | NA                  | NA                    |
| Body mass index (kg/m²)         | 1.01 (1.00–1.01)    | 0.004                 | 1.01 (1.00–1.01)    | 0.001                 |
| Diabetes mellitus               | 1.22 (0.91–1.64)    | 0.175                 | NA                  | NA                    |
| HBV                             | 1.32 (0.84–2.08)    | 0.231                 | NA                  | NA                    |
| Antithymocyte globulin vs. basiliximab | 0.87 (0.48–1.58) | 0.643                 | NA                  | NA                    |
| Tacrolimus vs. cyclosporin      | 1.34 (1.06–1.71)    | 0.015                 | 1.15 (0.89–1.48)    | 0.217                 |
| HLA-A, B, DR mismatch           | 1.07 (0.99–1.15)    | 0.074                 | 1.04 (0.96–1.12)    | 0.350                 |
| Rituximab                       | 0.76 (0.42–1.37)    | 0.363                 | 0.61 (0.34–1.11)    | 0.104                 |
| PRA class I                     | 1.00 (0.99–1.01)    | 0.163                 | NA                  | NA                    |
| PRA class II                    | 1.00 (0.99–1.01)    | 0.275                 | NA                  | NA                    |
| Living vs. cadaveric donor      | 1.08 (0.82–1.40)    | 0.598                 | NA                  | NA                    |

HR, hazard ratio; CI, confidence interval; HLA, human leukocyte antigen; PRA, panel reactive antibody; NA, not applicable.
rit+ group, respectively. The overall incidence rate of cancer after transplantation among the 3 study groups showed no significant difference (P = 0.340) (Fig. 3).

### Clinical characteristics and outcomes of hepatocellular carcinoma

Out of the 5,000 recipients, there were 238 patients (4.8%) who were chronic HBV carriers, and 4,762 (95.2%) who were non-HBV-infected patients. There were 8 chronic HBV carriers (3.4%) and 5 (non-HBV carriers 0.1%) who developed HCC (P < 0.001). The HCC-related mortality was 6 out of 8 cases (75.0%) in the HBV group and 2 out of 5 cases (40.0%) in the non-HBV group (P = 0.210). Among both the HBV and non-HBV carriers who were transplant recipients, only 1 patient who developed HCC was treated with rituximab for pretransplant desensitization. Six patients among 8 patients (75.0%) with HCC in the HBV group showed liver cirrhosis at the time of KT. Otherwise, there were no significant differences between HBV

| Table 3. Baseline characteristics between non-rituximab and rituximab groups in era2 after PSM |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Characteristic | Non-rituximab group | Rituximab group | SMD  |
| No. of patients | 1,391 | 610 | NA  |
| Age (yr) | 46.8 ± 12.0 | 47.0 ± 11.8 | 0.024 |
| Female sex | 582 (41.8) | 282 (46.2) | 0.089 |
| Diabetes mellitus | 361 (26.0) | 152 (24.9) | 0.024 |
| HBV | 59 (4.2) | 33 (5.4) | 0.055 |
| Body mass index (kg/m²) | 22.8 ± 3.52 | 22.6 ± 3.43 | 0.052 |
| HLA-A, -B, -DR mismatch | 3 (2–4) | 3 (2–5) | 0.098 |
| Calcineurin inhibitor | 1,107 (79.6) | 493 (80.8) | 0.031 |
| Tacrolimus | 284 (20.4) | 117 (19.2) |  |
| Cyclosporin | 42 (3.0) | 12 (2.0) |  |

Values are presented as number (%), mean ± standard deviation, and median (interquartile range).

PSM, propensity score matching; SMD, standardized difference; NA, not applicable; HLA, human leukocyte antigen; NA, not applicable.

Cox proportional hazards analysis after PSM.

Non-rituximab vs. rituximab (reference): HR, 1.36; 95% CI, 0.72–2.57; P = 0.348.

| Table 4. Cancer-related mortality rate and relative risk of patient death |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Variable | Mortality ratea, n (%) | Cancer-related death |
| | | HR (95% CI) | P-value |
| Total | 58/310 (17.1) | 1.62 (0.44–5.95) | 0.471 |
| Stomach cancer | 7/25 (28.0) | 0.52 (0.11–2.36) | 0.395 |
| Colorectal cancer | 3/11 (27.3) | 8.29 (2.40–28.69) | 0.001 |
| Hepatocellular carcinoma | 8/13 (61.5) | 5.41 (1.46–20.12) | 0.012 |
| Biliary-pancreatic cancer | 7/13 (53.8) | NA | NA |
| Skin cancer | 1/26 (3.8) | 1.46 (0.35–6.10) | 0.602 |
| Lung cancer | 5/16 (31.3) | 4.54 (0.98–21.04) | 0.053 |
| Oropharyngeal cancer | 3/9 (33.3) | NA | NA |
| Kaposi sarcoma | 0/11 (0) | 2.66 (0.28–24.98) | 0.393 |
| Liposarcoma | 1/2 (50.0) | 0.57 (0.10–3.22) | 0.522 |
| Breast cancer | 3/26 (11.5) | 2.17 (0.37–12.83) | 0.392 |
| Cervical cancer | 2/9 (22.2) | 0.92 (0.27–3.16) | 0.900 |
| Urologic cancer | 8/53 (15.1) | 1.02 (0.27–3.72) | 0.978 |
| Thyroid cancer | 5/40 (12.5) | 0.79 (0.28–2.22) | 0.650 |

Cox proportional hazards regression was performed among patients with malignant disease after adjusting for the following risk factors: age, body mass index, sex, diabetes mellitus, and rituximab treatment.

NA, not applicable.
aMortality rate due to malignant disease progression.
and non-HBV carriers who developed HCC, including age, sex, Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, and α-FP level (Table 5). The clinical course and outcomes of 13 patients who developed HCC are shown in Table 6. After adjusting for age, DM, BMI, sex, rituximab, CNI, HBV, and HCV, we found that HBV (HR, 25.2; 95% CI, 7.94–79.86; P < 0.010) was the only significant risk factor for the development of HCC in the multivariate regression analysis.

**DISCUSSION**

Our study revealed that rituximab did not affect the incidence of overall cancer development or that of each type of cancer. The malignancy-related mortality rate also showed no difference between the era2-rit– and era2-rit+ groups. The overall cancer incidence rate (310 cases, 6.2%) and mortality rate (58 cases, 1.2%) during 136 ± 87 months of the follow-up period were similar to those reported in recent studies [3,20]. However, our cohort had a relatively higher incidence and mortality rate of HCC than those in other studies performed in nonendemic area of HBV infection [3,20]. HCC was associated with the highest risk of cancer-related mortality among all cancer types that developed after transplantation in our study.

There has been little research on the risk of secondary malignancies due to rituximab treatment. Schrezenmeier et al. [13] reported that only 1 case of malignancy among 63 patients treated with rituximab. Bachelet et al. [11] also did not find an association between rituximab and an increased risk of posttransplant malignancy even though the recipients received antithymocyte globulin induction. These studies were conducted on a small number of patients to evaluate the effect of rituximab. By studying 622 patients who received rituximab, we evaluated the association between rituximab and cancer occurrence following transplantation more fully than recent studies. Although the follow-up period between the era1 and era2 groups was different, considering that the effects of rituximab usually do not exceed 12 months, our results were obtained with a sufficient observation period [9].

T-cell depletion with induction treatment and maintenance with tacrolimus rather than cyclosporin have been reported as risk factors for developing de novo tumors after transplantation [21]. Rituximab has been reported to increase the risk of secondary solid tumors in lymphoma treatment with high-

**Table 5. Clinical characteristics of patients with HCC after transplantation**

| Characteristic                  | HBV group (n = 8) | Non-HBV (n = 5) | P-value |
|---------------------------------|-------------------|----------------|---------|
| Incidence rate                  | 8/238 (3.4)       | 5/4,762 (0.1)  | <0.001  |
| HCC diagnosis since KT (mo)     | 48 (11–120)       | 78 (21–130)    | 0.420   |
| HCC-related mortality           | 6 (75.0)          | 2 (40.0)       | 0.207   |
| Age (yr)                        | 44.0 ± 11.6       | 45.4 ± 3.6     | 0.755   |
| Male sex                        | 8 (100)           | 3 (60.0)       | 0.128   |
| Living donor                    | 8 (100)           | 4 (80.0)       | 0.385   |
| Rituximab                       | 1 (12.5)          | 1 (20.0)       | >0.999  |
| Liver cirrhosis at KT           | 6 (75.0)          | 0 (0)          | 0.021   |
| Child-Pugh score<sup>b</sup>    | 6.0 (5.0–7.5)     | 6.0 (5.5–8.0)  | 0.206   |
| MELD score<sup>c</sup>          | 9.0 (8.3–15.5)    | 8.0 (6.5–11.5) | 0.763   |
| α-FP (ng/mL)                    | 93 (6–1,269)      | 20 (1–6,950)   | >0.999  |

Values are presented as number (%), median (interquartile range), or mean ± standard deviation. HCC, hepatocellular carcinoma; KT, kidney transplantation; MELD, Model for End-Stage Liver Disease.

<sup>a</sup>Patients with positive hepatitis B surface antigen. <sup>b</sup>Values at hepatocellular carcinoma diagnosis.
dose chemotherapy [22]. However, B-cell depletion associated with single-dose rituximab does not seem to have enough of an impact on the development of cancer.

Rituximab increases complication rates from infectious diseases, including viral, bacterial, and fungal infections, mostly when a dosage greater than standard-dose rituximab (375 mg/m²) is used [5,23]. Recent studies have shown that viral infections such as infections with human herpesvirus type 9, Epstein Barr virus, human papillomavirus, HBV, and HCV increase the risk of malignant disease associated with their pathogenesis [24]. Therefore, in contrast to our study results, we assumed that rituximab could increase the rate of cancer development. One of the reasons we suspect that rituximab did not increase the cancer risk was that a low dose of less than 200 mg/m² was used. We previously experienced lethal infectious complications when we used a desensitization protocol with 500 mg of rituximab [5]. After modifying the protocol to use 200 mg of rituximab, we significantly reduced the infectious complications and achieved a patient survival rate similar to that achieved with ABO- and HLA-compatible recipients [5]. Although 102 patients who received 500 mg of rituximab did not have increased cancer incidence or cancer-related mortality in our multivariate analysis, considering that 7 patients died due to early complications and only a small number of patients received 500 mg of rituximab, the modified desensitization protocol seemed to play a critical role in reducing infectious complications and related malignancies. In addition, recent research has shown that reduced-dose rituximab can prevent HBV reactivation after transplantation [25].

HBV infection is the primary cause of HCC, accounting for up to 75% of HCC cases [26]. Our study also showed that patients with HBV had a significantly higher rate of HCC after KT than those without HBV. The incidence rate of HCC (3.4%) in HBV-infected patients in our study was similar to the results of Kanaan et al. [17], showing outcomes of HBV- and HCV-associated HCC after KT. The incidence rate appears to be lower than that of the general population possibly because only patients with compensated liver cirrhosis underwent KT and recipients were thoroughly screened before and after transplantation. Although we did not find a relationship between HCC incidence and rituximab, the risk of cancer-related mortality was the highest in HCC among all kinds of cancer. All 8 patients who developed HCC among HBV-infected patients underwent pre- and postoperative screening examinations as scheduled. However, 6 patients died due to HCC aggravation, and 2 patients among these 6 patients developed HCC within 6 months after transplantation. Therefore, the current guidelines for HCC for patients with HBV infection may need to be modified in terms of the diagnostic modalities and testing period. Six out of 8 patients who developed HCC had liver cirrhosis identified on preoperative nonenhanced CT or USG. Currently, USG is the backbone of HCC surveillance [19]. Nevertheless, a recent meta-analysis reported that the sensitivity of USG is low for identifying early-stage HCC in patients with liver cirrhosis [27]. CT and MRI have been suggested to be more accurate diagnostic tools [27-29]. Pocha et al. [29] reported that CT showed no significant differences in sensitivity and sensitivity from USG for detecting any stage of HCC. Kim et al. [28] demonstrated that MRI with liver-specific contrast had a higher HCC detection rate than USG in patients with cirrhosis. The surveillance interval is also an important factor in detecting early HCC in patients with cirrhosis. There was a report that a surveillance interval with USG within 6 months improved sensitivity for diagnosing

### Table 6. Summary of clinical courses of HCC after transplantation

| No | HBVa | Location | Size (cm) | Treatment | Survival | Timeb (mo) |
|----|------|----------|-----------|-----------|----------|------------|
| 1  | +    | S6       | 2.2       | TACE#4 + RFA#1 | Death   | 107        |
| 2  | +    | S6       | 6         | TACE#3 + RFA#4 | Death   | 57         |
| 3  | +    | RL       | Huge      | Conservative | Death   | 128        |
| 4  | +    | Multiple | 3         | Conservative | Death   | 4          |
| 5  | +    | S8       | 5         | TACE #4     | Death   | 32         |
| 6  | +    | S2       | 5         | TACE #3     | Survival| 122        |
| 7  | +    | S5       | 1.8       | RPS        | Survival| 40         |
| 8  | +    | S8       | 3.6       | TACE #2     | Death   | 5          |
| 9  | –    | LL       | 8.5       | Left lobectomy | Survival| 132        |
| 10 | –    | S6       | 4         | Liver transplantation | Survival| 79         |
| 11 | –    | S5       | 0.9       | SS segmentectomy | Survival| 128        |
| 12 | –    | S4       | 5.8       | LMS        | Death   | 34         |
| 13 | –    | LL       | Huge      | Conservative | Death   | 8          |

HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; RL, right lobe; LL, left lobe; RPS, right posterior sectionectomy; LMS, left medial sectionectomy.
aPatients with positive hepatitis B surface antigen. bTime from kidney transplantation to HCC diagnosis.
early HCC compared with annual surveillance [30]. Additional enhanced CT or MRI scans as preoperative screening tools may prevent aggravation of hidden HCC after transplantation in patients with HBV and cirrhosis. We also recommend that recipients with liver cirrhosis undergo surveillance tests at least every 6 months.

Our study has limitations due to its retrospective nature and because it was conducted in a single center for over 30 years. The immunosuppressive protocols, antiviral therapy for HBV, and diagnostic techniques and treatment options for malignant diseases have been changed. To overcome confounders associated with time variation, we performed a Cox proportional hazards regression analysis and divided the study groups according to the era. We did not compare cancer risk and cancer-related mortality in our cohort with those in the general population. We focused on evaluating the risks associated with rituximab treatment in KT recipients. In addition, as most of the recipients enrolled in this study were of Asian descent, our results may not be applicable to patients of other races. However, this study yielded a novel finding about HBV-carrying recipients by including a relatively large number of patients compared with nonendemic areas. Finally, cancer that occurred among patients who were not followed up in our center may have led to an underestimation of the incidence of malignant tumors. However, our study was able to utilize more accurate information as a single institutional study compared to a large-scale cohort study.

Our results suggest that single-dose rituximab for desensitization may not increase the risk of malignant disease or cancer-related mortality in recipients undergoing KT. HCC was associated with the highest risk of cancer-related mortality in our study cohort. To reduce the HCC-related mortality, enhanced CT or MRI can be helpful diagnostic modalities to enhance the sensitivity and specificity for early detection of HCC in patients with liver cirrhosis. We also recommend that the surveillance interval not exceed 6 months.

ACKNOWLEDGEMENTS

We would like to express our sincere appreciation to Professor Duck-Jong Han. Professor Duck-Jong Han founded the kidney and pancreas transplant programs at Asan Medical Center and performed more than 6,000 kidney transplants and 500 pancreas transplants. Hyunwook Kwon would like to say special thanks to his principal supervisor, Professor Yong-Pil Cho.

Conflict of Interest

The authors report having no conflicts of interest associated with this manuscript.

ORCID iD

Hayoung Lee: https://orcid.org/0000-0002-9637-3746
Young Hoon Kim: https://orcid.org/0000-0003-3840-8426
Seong Jun Lim: https://orcid.org/0000-0002-4969-2787
Youngmin Ko: https://orcid.org/0000-0002-4148-4916
Sung Shin: https://orcid.org/0000-0001-7318-4208
Joo Hee Jung: https://orcid.org/0000-0003-1081-9282
Chung Hee Baek: https://orcid.org/0000-0001-7611-2373
Hyo Sang Kim: https://orcid.org/0000-0001-8140-9534
Su-Kil Park: https://orcid.org/0000-0001-7242-7204
Hyunwook Kwon: https://orcid.org/0000-0001-5018-5304

Author Contribution

Formal Analysis: HL, YHK, SKP, H Kwon
Investigation: HL, YK, SJL, SS, JHJ, H Kwon
Methodology: HL, CHB, H Kim, H Kwon
Project Administration: HL, YHK, SKP, H Kwon
Writing – Original Draft: HL, H Kwon
Writing – Review & Editing: All authors

REFERENCES

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
2. Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant 2009;9:1868-75.
3. Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, et al. Mortality risk after cancer diagnosis in kidney transplant recipients: the limitations of analyzing hospital administration data alone. Cancer Med 2018;7:931-9.
4. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006;81:1227-33.
5. Kwon H, Kim YH, Choi JY, Sung S, Jung JH, Park SK, et al. Analysis of 4000 kidney transplantations in a single center: across immunological barriers. Medicine (Baltimore) 2016;95:e4249.
6. Echterdiek F, Latus J, Schwenger V. Immunosuppression in sensitized recipients. Curr Opin Organ Transplant
7. Speer C, Kälble F, Nusshag C, Pego da Silva L, Schaier M, Becker LE, et al. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption: a retrospective study. Transpl Int 2019;32:1286-96.

8. Kim JM, Park H, Jang HR, Park JB, Kwon CH, Huh W, et al. High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients. Ann Surg Treat Res 2014;86:256-63.

9. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007;84(12 Suppl):S33-6.

10. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov 2017;7:1306-19.

11. Bachelet T, Visentin J, Davis P, Taton B, Guidicelli G, Kaminski H, et al. The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab. Clin Transplant 2021;35:e14171.

12. Yang CY, Lee CY, Yeh CC, Tsai MK. Renal transplantation across the donor-specific antibody barrier: graft outcome and cancer risk after desensitization therapy. J Formos Med Assoc 2016;115:426-33.

13. Schrezenmeier E, Budke K, Staeck O, Lehner L, Duer M, Khadzhynov D, et al. Incidence of infectious disease and malignancies after rituximab therapy in kidney transplant recipients: results from a cohort in Germany. Transplant Proc 2017;49:2269-73.

14. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab for lymphoma. J Clin Oncol 2011;29:814-24.

15. Kim YH, Kim JY, Kim DH, Ko Y, Choi JY, Shin S, et al. Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab. BMC Nephrol 2020;21:93.

16. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.

17. Kanaan N, Raggi C, Goffin E, De Meyer M, Mourad M, Jadoul M, et al. Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. J Viral Hepat 2017;24:430-5.

18. Yun EH, Hong S, Her EY, Park B, Suh M, Choi KS, et al. Trends in participation rates of the National Cancer Screening Program among cancer survivors in Korea. Cancers (Basel) 2020;12:81.

19. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 Suppl 3;S1-155.

20. Pedotti P, Cardillo M, Rossini G, Arcuri V, Boschiero L, Caldara R, et al. Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation 2003;76:1448-51.

21. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87-93.

22. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Guelli A, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011;29:814-24.

23. Lee J, Lee JG, Kim S, Song SH, Kim BS, Kim HO, et al. The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2016;31:1031-21.

24. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582-8.

25. Lee J, Park JY, Kim DG, Lee JY, Kim BS, Kim MS, et al. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 2018;8:15629.

26. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67.

27. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients at risk of cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.

28. Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 2017;3:456-63.

29. Pocha C, Dieperink E, Mcmaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography: a randomised study. Aliment Pharmacol Ther 2013;38:303-12.

30. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.